Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSKIRA-4: Fostamatinib Disodium Monotherapy vs Adalimumab Monotherapy in Active Rheumatoid Arthritis
2010-023692-26Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fostamatinib in rheumatoid arthritis (RA) (3 arms), sponsored by AstraZeneca. Primary endpoints: DAS28 at Week 6 and DAS28 at Week 24. Started Nov 2010; status: terminated.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-023692-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023692-26.